Van ECK Associates Corp Invests $725,000 in Hologic, Inc. (NASDAQ:HOLX)

Van ECK Associates Corp acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 8,918 shares of the medical equipment provider's stock, valued at approximately $725,000.

Other large investors also recently bought and sold shares of the company. Prentiss Smith & Co. Inc. increased its stake in shares of Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider's stock worth $3,967,000 after acquiring an additional 130 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its position in Hologic by 20.3% during the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider's stock worth $62,000 after purchasing an additional 140 shares during the last quarter. Wedmont Private Capital raised its stake in Hologic by 3.7% during the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider's stock worth $361,000 after purchasing an additional 162 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in Hologic by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider's stock valued at $536,000 after purchasing an additional 165 shares during the last quarter. Finally, Curbstone Financial Management Corp grew its stake in shares of Hologic by 0.9% in the 2nd quarter. Curbstone Financial Management Corp now owns 23,126 shares of the medical equipment provider's stock valued at $1,717,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Down 0.1 %

Shares of HOLX stock traded down $0.06 during trading on Tuesday, reaching $79.33. The company's stock had a trading volume of 294,988 shares, compared to its average volume of 1,585,621. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The stock's 50-day moving average price is $80.93 and its 200 day moving average price is $78.19. The company has a market capitalization of $18.43 billion, a price-to-earnings ratio of 23.84, a P/E/G ratio of 2.48 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.32.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company's quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.89 earnings per share. On average, research analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on HOLX shares. Stephens reaffirmed an "overweight" rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Evercore ISI lifted their target price on Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a research report on Tuesday, October 1st. Mizuho lowered their price target on Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Tuesday, November 5th. StockNews.com downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Wednesday, November 6th. Finally, Leerink Partners decreased their target price on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $89.25.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.